All Type of News
Demo Project for Chronic Disease Management starts September
The Demo Project for Chronic Disease Management Including Telephone Counseling will be actively implemented from September.
The Ministry of Health and Welfare(MOHW) announced it will take applications from medical in...
Series of blockbuster drugs to be expired in patent at the year end
At the end of this year, a series of large blockbuster drugs including an antidiabetic ‘Twynsta’ will be expired in patent, and a follow-up great war of generics is about to occur.
According to the pharmaceutical ind...
Celltrion’s Remsima & Samsung’s SB5 about to be launched in US and Europe
Celltrion(CEO Jung-jin Seo) and Samsung Bioepis(CEO Han-seung Ko) got a step closer to pioneering the U.S. and European markets.
According to the industry concerned, a U.S. patent suit on a Celltrion’s Remicade biosi...
“Companies must approach conservatively to Kim Young-ran Law”
Compliance Program managers at pharmaceutical companies got together and made a discussion about the ‘Confrontational Strategy to Kim Young-ran Law.’
CP managers poured out questions after listening to lectures of e...
Novartis only to avoid problems, “We didn’t know about KRW 18 billion”The prosecution has once again exposed hidden connections between pharmaceutical companies and doctors in large general hospitals. The subject of the issue is a large global pha...
|
Reason why Novartis’ trial will become Moon’s battle
Hak-sun Moon(47), a former CEO of Novartis Korea, was indicted without detention only in 11 months after the appointment.
The Seoul Western District Prosecutor’s Office is suspicious on the former Novartis Korea CEO...
“Our goal is to reduce antibiotic prescriptions by half in 5 years”
The government held the 86th National Policy Coordination Meeting hosted by Prime Minister Gyo-ahn Hwang at the Central Government Complex on the 11th, and confirmed the ‘National Antibiotic Resistance Management Plan...
Serious abuses in direct dealing to hospitals, will government leave as it is?
Direct wholesale to hospitals has become a hot potato once again. In particular, the industry has shown different reactions to the previous issues.
The Korea Pharmaceutical Distribution Association started prepara...
Brilinta’s 1-year administration obstacle will be removed by low volume
The AstraZeneca’s anticoagulant Brilinta(generic name: ticagrelor) was also approved in a low volume, 60mg, followed by its 90mg volume.
Brilinta 90mg can only be prescribed for a year in combination with aspirin. H...
Oral rheumatoid arthritis therapy, Xeljanz, attempting for insurance as secondary treatment
An oral rheumatoid arthritis treatment ‘Xeljanz’ starts a move to recover its position as a practical secondary treatment.
According to the industry concerned on the 12th, the Pfizer’s janus kinase(JAK) inhibitor Xe...
